Biogen and AbbVie pull MS drug Zinbryta from the market

Potential risks of liver damage and immune-related conditions have been reported

Original Article: Biogen and AbbVie pull MS drug Zinbryta from the market

More From BioPortfolio on "Biogen and AbbVie pull MS drug Zinbryta from the market"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications